DBV Technologies reports FY2023 net loss $72.7M; cash $141.4M; substantial doubt about going concern

DBV Technologies S.A.

Net loss $72.7M ($0.76/share) vs $96.3M in 2022; operating expenses $92.2M, with R&D $60.2M.
Cash and equivalents $141.4M as of Dec 31, 2023, down from $209.2M; projected to fund operations only through Dec 31, 2024.
VITESSE Phase 3 trial for ages 4-7: last patient screening expected Q3 2024; COMFORT Toddlers and Children safety trials to initiate.
Substantial doubt about ability to continue as going concern; company intends to seek additional debt and equity capital.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DBV Technologies S.A. reported financial results for full year 2023.

Period: full year 2023
Result: reported results

Exact text from the filing

On March 7, 2024, DBV Technologies S.A. (the “Company”) issued a press release announcing the full year financial results and business update for the year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

DBV Technologies S.A. filing history →

Source: SEC EDGAR

accession 0001193125-24-062338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.